Rapid Information on OLM No.168 121208.doc

Rapid Information on Olmesartan and other ARBs No.168 2012/12/08 　　　　　　　　　　　　　　　　　 　　　　　　　　Be the first to know! 　　　 　　 (Toru Komai, Ph.D.) 168-1: Olmesartan improves cardiac remodeling and function via DLL4/Notch1 pathway activation in mice with chronic pressure overload. Title: Olmesartan attenuates cardiac remodeling through DLL4/Notch1 pathway activation in pressure overload mice. 2-3 168-2: Switching to a fixed-dose combination of AML/OM?HCTZ effectively controlled BP to target in a large proportion of obese patients with hypertension who were previously uncontrolled on antihypertensive monotherapy. Title: Efficacy of amlodipine/olmesartan medoxomil?±?HCTZ in obese patients uncontrolled on antihypertensive monotherapy. 4 168-3：An overview of the evidence supporting the use of triple combination with different classes of antihypertensive drugs, with a particular focus on those based on olmesartan/amlodipine/HCTZ. Title: Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy. 5 168-1: Olmesartan improves cardiac remodeling and function via DLL4/Notch1 pathway activation in mice with chronic pressure overload. Human gene NOTCH encodes a member of the Notch family. Notch 1 protein, one of the Notch family members, functions as a receptor for membrane bound ligands, and may play a role in a variety of developmental processes by controlling cell fate decisions. Notch1 signaling also controls the cardiac adaptation to stress. ARBs are highly effective for the treatment of pressure overload-induced cardiac remodeling and heart failure. Therefore, in this study, the authors investigated whether olmesartan ameliorates cardiac remodeling and dysfunction via Delta-like ligand 4 (DLL4)/No